Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to find out how much of the drug raltegravir (RGV) gets into
cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal
changes in a certain gene in your body affects how much RGV gets into the CSF.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center